Original articleLOBAPLATIN (cas 135558-11-1) arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro
-
Add time:08/20/2019 Source:sciencedirect.com
Melanoma is highly resistant to most conventional treatment, and the incidence and mortality rates are increasing rapidly worldwide. The objective of this study was to determine the anticancer effects of lobaplatin on the melanoma carcinoma cell line B16-F10 in vitro, and explored its mechanisms of action. Our results have shown that lobaplatin inhibited cell proliferation in human melanoma A375 and CHL-1 cells and murine melanoma B16-F10 cells in a concentration- and time-dependent manner. Flow cytometry assay confirmed that lobaplatin affected B16-F10 cell survival by blocking cell cycle progression in G2/M phase and inducing apoptosis in a concentration-dependent manner. In addition, the apoptosis was associated with downregulation of anti-apoptotic protein Bcl-2 while upregulation of pro-apoptotic protein Bax. Lobaplatin could also decrease the mitochondrial membrane potential, indicating that lobaplatin may induce apoptosis via mitochondria-mediated apoptotic pathway. Furthermore, lobaplatin blocked B16-F10 cell migration and invasion in vitro. These results suggested that lobaplatin could be an effective chemotherapeutic agent in melanoma treatment by inhibiting proliferation, inducing apoptosis, cell cycle arrest and blocking cell migration and invasion.
We also recommend Trading Suppliers and Manufacturers of LOBAPLATIN (cas 135558-11-1). Pls Click Website Link as below: cas 135558-11-1 suppliers
Prev:LOBAPLATIN (cas 135558-11-1) induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion
Next:Research paperHydrolysis mechanism of anticancer drug LOBAPLATIN (cas 135558-11-1) in aqueous medium under neutral and acidic conditions: A DFT study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research paperHydrolysis mechanism of anticancer drug LOBAPLATIN (cas 135558-11-1) in aqueous medium under neutral and acidic conditions: A DFT study08/21/2019
- LOBAPLATIN (cas 135558-11-1) induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion08/19/2019
- Dose Escalation of LOBAPLATIN (cas 135558-11-1) Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial2308/18/2019
- Original articleAntitumor activity of LOBAPLATIN (cas 135558-11-1) against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio08/17/2019
- Original articleLOBAPLATIN (cas 135558-11-1)-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment08/16/2019
- Research paperSingle-nucleotide polymorphisms (rs342275, rs342293, rs7694379, rs11789898, and rs17824620) showed significant association with LOBAPLATIN (cas 135558-11-1)-induced thrombocytopenia08/15/2019
- LOBAPLATIN (cas 135558-11-1) suppresses proliferation and peritoneal metastasis of colorectal cancer in a preclinical model08/14/2019
- The antitumor effect of LOBAPLATIN (cas 135558-11-1) against Ishikawa endometrial cancer cells in vitro and in vivo08/13/2019


